NCT05659056View on ClinicalTrials.gov

Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

April 30, 2024

Study Completion Date

July 31, 2024

Conditions
Breast Cancer
Interventions
DRUG

Pyrotinib, trastuzumab, paclitaxel-albumin

pyrotinib: 400mg orally daily; trastuzumab: 8mg/kg iv load followed by 6mg/kg iv 3-weekly for a total of 6 cycles; paclitaxel-albumin: 260mg/m2, every 3 week, a total of 6 cycles

Trial Locations (1)

Unknown

RECRUITING

JiangSu Province Hospital/ The First Affiliated Hospital of Nanjing Medical University, Nanjing

All Listed Sponsors
collaborator

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

lead

The First Affiliated Hospital with Nanjing Medical University

OTHER